

1 **Impact of the COVID-19 Vaccination Program on Case** 2 **Incidence, Emergency Department Visits, and Hospital** 3 **Admissions among Children Aged 5–17 Years during the** 4 **Delta and Omicron Periods —United States, December 2020** 5 **to April 2022**

6 Katherine G Topf, MPH¹, Michael Sheppard, MS², Grace E. Marx, MD³, Ryan E Wiegand,
7 PhD², Ruth Link-Gelles, PhD³, Alison M Binder, MS², Andrea J Cool, MPH¹, B. Casey Lyons,
8 MPH², Sohyun Park, PhD², Hannah E Fast, MPH², Arthur Presnetsov¹, G Roseric Azondekon,
9 PhD², Karl A Soetebier, MAPW², Jennifer Adjemian, PhD³, Kamil E Barbour, PhD³

10 Affiliations

11 ¹Booz Allen Hamilton, McLean, VA, USA.

12 ²CDC COVID-19 Response Team, U.S. Centers for Disease Control and Prevention, Atlanta,
13 GA, USA.

14 ³CDC COVID-19 Response Team, U.S. Centers for Disease Control and Prevention, Atlanta,
15 GA, USA; U.S. Public Health Service Commissioned Corps, Atlanta, GA, USA.

16

17 **Target Journal:** PLoS ONE

18 **Word count:** 2822

19 **Abstract:** 250

20 **Tables:** 2 and **Figures:** 2 (**Appendix Tables:** 2)

21 **Funding:** This work was supported by the CDC's regular operating funds. The CDC was
22 involved in the study design, data analysis, data interpretations, and writing and submission of
23 the report.

24 **CDC Disclaimer:** The findings and conclusions in this report are those of the author(s) and do
25 not necessarily represent the official position of the Centers for Disease Control and Prevention
26 (CDC).

27 **Corresponding Author:**

28 Kamil Elie Barbour, PhD, MPH, MS

29 4770 Buford Highway

30 Atlanta, GA, 30341

31 Email: iyk1@cdc.gov

32

33

34 **Abstract**

35 **Background:** In the United States, national ecological studies suggest a positive impact of
36 COVID-19 vaccination coverage on outcomes in adults. However, the national impact of the
37 vaccination program on COVID-19 in children remains unknown. To determine the association
38 of COVID-19 vaccination with U.S. case incidence, emergency department visits, and hospital
39 admissions for pediatric populations during the Delta and Omicron periods.

40 **Methods:** We conducted an ecological analysis among children aged 5–17 and compared
41 incidence rate ratios (RRs) of COVID-19 cases, emergency department visits, and hospital
42 admissions by pediatric vaccine coverage, with jurisdictions in the highest vaccine coverage
43 quartile as the reference.

44 **Results:** RRs comparing states with lowest pediatric vaccination coverage to the highest pediatric
45 vaccination coverage were 2.00 and 0.64 for cases, 2.96 and 1.11 for emergency department visits,
46 and 2.76 and 1.01 for hospital admissions among all children during the Delta and Omicron
47 periods, respectively. During the 3-week peak period of the Omicron wave, only children aged
48 12–15 and 16–17 years in the states with the lowest versus highest coverage, had a significantly
49 higher rate of emergency department visits (RR=1.39 and RR=1.34, respectively).

50 **Conclusions:** COVID-19 vaccines were associated with lower case incidence, emergency
51 department visits and hospital admissions among children during the Delta period but the
52 association was weaker during the Omicron period. Pediatric COVID-19 vaccination should be
53 promoted as part of a program to decrease COVID-19 impact among children; however, vaccine
54 effectiveness may be limited when available vaccines do not match circulating viral variants.

55

56

57

58 **Introduction**

59 In the United States, Pfizer-BioNTech was recommended on December 12, 2020, for children aged
60 16–17 years, May 12, 2021, for children aged 12–15 years, and November 2, 2021, for children
61 aged 5–11 years^[1-3]. As of May 6, 2022, 62.6% of children aged 16–17 years, 57.6% of children
62 aged 12–15 years, and 28.8% of children aged 5–11 years were fully vaccinated with the Pfizer-
63 BioNTech COVID-19 vaccination series^[4].

64 Although children are less likely to develop severe COVID-19 compared to adults, the pandemic
65 has nonetheless had a serious direct and indirect negative impact on children^[5]. Among children
66 aged <18 years, 12,752,227 cases and 1,536 deaths due to COVID-19 have been reported as of
67 May 16, 2022^[6]. Children can also suffer delayed sequelae from COVID-19 including multisystem
68 inflammatory syndrome which usually requires hospitalization and can result in disability and
69 death^[7]. In addition, isolation during infection and quarantine after exposure to sick contacts results
70 in fewer days in school where children can access nutritious food and social and mental health
71 support^[8].

72 Prior U.S. national studies of adult populations have shown that people living in areas where
73 COVID-19 vaccination of adults is higher have lower case incidence, lower hospitalization rates,
74 and fewer emergency department visits due to COVID-19^[9-10]. With the introduction of pediatric
75 COVID-19 vaccinations, it is important to assess this impact among children. Previous studies
76 indicate vaccines are effective for the prevention of infection and hospitalization, though the
77 effectiveness is lower during Omicron circulation than for previous variants^[11-13]. We conducted
78 an ecological study to determine the association of state-level COVID-19 vaccination rates with
79 case incidence, emergency department visits, and hospital admissions in the pediatric population

80 during two crucial periods of the COVID-19 pandemic when the Delta and Omicron variants
81 predominated.

82 **Methods**

83 **Study Design**

84 To assess the impact of pediatric vaccination coverage on COVID-19 in children, we analyzed
85 weekly time series data for COVID-19 cases, emergency department visits with diagnosed
86 COVID-19, and hospital admissions of patients with lab-confirmed positive SARS-CoV-2 results
87 from December 13, 2020, to April 30, 2022. We stratified data for COVID-19 cases and emergency
88 department diagnoses by pediatric age groups for children aged 5–11, 12–15, and 16–17 years; we
89 included aggregated hospital weekly admission data among children aged 0–17 years. We defined
90 the analytic period to capture periods before and after COVID-19 vaccine was authorized for each
91 pediatric age group. To compare outcomes in jurisdictions (U.S. states and the District of
92 Columbia) in the lowest quartile for pediatric vaccination coverage to jurisdictions in the highest
93 quartile for pediatric vaccination coverage, we calculated rate ratios with high coverage
94 jurisdictions used as the reference group for: 1) all weeks included in the analytical period; and 2)
95 date ranges aligning with predominance of the Delta and Omicron variants in the United States,
96 and the 3-week peak periods of Delta and Omicron waves. We aggregated county-level
97 vaccination coverage data into jurisdiction-level data and then grouped jurisdictions into
98 vaccination coverage categories using quartiles for vaccination coverage rate estimates for children
99 aged 5–17 years as of April 2022.

100 This activity was reviewed by the Centers for Disease Control and Prevention’s (CDC) Human
101 Research Protection Office and determined to be exempt from human participants’ research
102 regulations, including the need for documented written consent, as the activities involved

103 identification, control or prevention of disease in response to an immediate public health threat. It
104 was conducted consistent with applicable federal law and CDC policy (See e.g., 45 C.F.R. part 46,
105 21 C.F.R. part 56; 42 U.S.C. §241(d); 5 U.S.C. §552a; 44 U.S.C. §3501 et seq.).

106 **Data Sources**

107 **Cases**

108 Jurisdictional (state (50), territorial (3) and local (2)) health departments voluntarily submit de-
109 identified individual-level data for COVID-19 cases to CDC via the COVID-19 Case Report Form
110 and the National Notifiable Diseases Surveillance System^[14-15]. These data sources are aggregated
111 for use as a single dataset. Age was available for 99% of recorded cases. In this analysis, we used
112 data from 33 states, representing 70% of US population under age 18; we excluded jurisdictions if
113 less than 80% of records contained residential county information, if less than 90% of records
114 contained relevant date information, or if the jurisdiction was missing data for more than 1 week
115 in the study period. Jurisdictions included were Alabama, Arizona, Arkansas, California,
116 Colorado, Delaware, Georgia, Idaho, Illinois, Indiana, Kansas, Louisiana, Maine, Massachusetts,
117 Minnesota, Missouri, Montana, Nevada, New Jersey, New Mexico, New York, North Carolina,
118 North Dakota, Ohio, Oregon, Pennsylvania, South Carolina, Tennessee, Utah, Vermont, Virginia,
119 Washington, and Wyoming.

120 **Emergency Department Visits**

121 We collected emergency department visit data from the National Syndromic Surveillance Program
122 (NSSP), representing encounters with a diagnosis of COVID-19, defined by having any of the
123 following discharge diagnoses: International Classification of Diseases, Tenth Revision codes
124 U07.1 or J12.82 or Systematized Nomenclature of Medicine (SNOMED) codes 840539006,
125 84054404, or 840533007. NSSP collects electronic health data from 73% of non-federal hospital

126 facilities across all jurisdictions^[16]. We applied data quality filters to only include data from
127 facilities with high completeness of discharge diagnoses (average weekly completeness $\geq 75\%$)
128 and consistent reporting over the analytic period. Fewer than 50% of facilities in California,
129 Hawaii, Iowa, Minnesota, and Oklahoma send data to the NSSP; we excluded emergency
130 department visit data from these jurisdictions from this analysis. Additionally, we excluded
131 jurisdictions with low completeness for discharge diagnoses (Missouri) and those with missing
132 data during the analytical period (Maryland).

133 **Hospital Admissions**

134 De-identified COVID-19 hospitalization data are reported by over 6,000 hospitals in the United
135 States through the U.S. Department of Health and Human Services Unified Hospital Data
136 Surveillance System (UHDSS), which collects daily hospital-level data from all hospitals
137 registered with the Centers for Medicare and Medicaid Services (CMS) as of June 1, 2020, and
138 data from hospitals not registered with CMS but reporting since July 15, 2020^[17]. Facility subtype
139 designations are determined by CMS. We excluded psychiatric, rehabilitation, and religious non-
140 medical facilities from analyses, because these facilities are required to report per conditions of
141 participation, but do not typically treat or admit patients with acute COVID-19. Data included in
142 analyses represent all jurisdictions and were both consistent and complete during the analytic
143 period (at least 5146 [98%] of 5251 hospitals meeting inclusion criteria reported COVID-19
144 admissions data on any given day between December 13, 2020, and April 30, 2022). New
145 admissions of pediatric patients aged 0 – 17 years with confirmed COVID-19 obtained from
146 UHDSS were available as aggregate counts reported daily during the study period. Reporting of
147 new admissions of patients with confirmed COVID-19 by narrower age ranges (0–4, 5–11, and
148 12–17 years) began in February 2022. Thus, we conducted analyses of pediatric hospital

149 admissions data for children aged 0–17 years; further stratification by age was not possible due to
150 limited availability of the more granular age-specific admissions data.

151 **Vaccine Administration Data**

152 Individual-level COVID-19 vaccine administration data are submitted to CDC via jurisdictional
153 immunization information systems, the Vaccine Administration Management System, or direct
154 data submission^[18-19]. The data are de-duplicated, de-identified, and subjected to systematic quality
155 control checks prior to analysis^[20]. For this analysis, we included Pfizer-BioNTech vaccines
156 administered to children aged 5–17 years by April 30, 2022, in all reporting jurisdictions.

157 **Statistical Analysis**

158 We used U.S. 2019 population estimates to calculate jurisdiction pediatric vaccination coverage
159 rates and cases and hospital admission rates per 100,000 population^[21]. We calculated jurisdiction
160 pediatric vaccination coverage quartiles using cumulative percentages for children aged 5–17 years
161 who had completed the COVID-19 vaccination series. To estimate rate ratios comparing
162 jurisdictions with lower vaccination coverage (lowest, second lowest, and second highest
163 vaccination coverage quartiles) to jurisdictions in the highest vaccination coverage quartile, we
164 used Poisson regression models and generalized estimating equations (GEE) to account for
165 clustering of data by state. We calculated 95% confidence intervals (CIs) using robust standard
166 errors.

167 We calculated ratios for emergency department visits using the total number of visits rather than
168 population-based estimates. To assess differences in lower and highest vaccination coverage
169 jurisdictions over time, we calculated rate ratios for case counts, emergency department visits, and
170 hospital admissions for: 1) all weeks from December 13, 2020, to April 30, 2022; 2) time periods
171 aligning with predominance of the Delta and Omicron variants in the United States (Delta: June

172 20, 2021–October 31, 2021; Omicron: December 19, 2021–April 30, 2022); and 3) 3-week time
173 periods aligning with peaks in case incidence during the Delta and Omicron variant time periods
174 (Delta: August 22, 2021–September 11, 2021; Omicron: January 2, 2022–January 22, 2022). We
175 calculated jurisdiction coverage quartiles separately for the Delta and Omicron time periods, using
176 coverage estimates from the mid-point of each period (Delta: September 5, 2021; Omicron:
177 February 20, 2022). For weekly rate ratio calculations, we used coverage estimates as of April 30,
178 2022 to determine jurisdictions in the lowest and highest (reference) coverage quartiles. We kept
179 jurisdictions in the lowest and highest coverage quartiles fixed over the analytic period for weekly
180 rate ratio calculations. For COVID-19 cases and emergency department visits, we calculated rate
181 ratios separately for children aged 5–11, 12–15, and 16–17 years, and for children aged 5–17 years
182 overall. Rate ratio calculations for hospital admissions were limited to children aged 0–17 years.
183 We used R version 4.3.1 for all statistical analyses.

184

185 **Results**

186 As of April 30, 2022, vaccination coverage remained highest for children aged 16–17 years
187 (62.8%), followed by children aged 12–15 (56.7%) and 5–11 (27.3%) years (Figure 1). For the age
188 groups of 5–11 and 12–15 years, the increase in vaccination coverage was greatest in the first 1–2
189 months following FDA Emergency Use Authorization and CDC recommendation of the COVID-
190 19 and slowed dramatically in subsequent months.

191

192

193


194

195

196

197 **Figure 1:** Weekly “fully vaccinated” pediatric vaccination coverage rates by age group among
 198 children aged 5–17 years, U.S., from December 13, 2020, through April 30, 2022

Full Vaccination Coverage by Pediatric Age Group
 December 13, 2020 to April 30, 2022



199
 200
 201 During the Delta and Omicron periods of predominance in the US, case incidence and the
 202 percentage of emergency department visits with diagnosed COVID-19 in children aged 5–17 years
 203 were 4,206 per 100,000 persons (cases) and 3.24% (emergency department visits) during the Delta
 204 period, and 8,724 per 100,000 persons (cases) and 3.81% (emergency department visits) during
 205 the Omicron period. Hospital admission rates in children aged 0–17 years during the Delta and
 206 Omicron periods were 37 per 100,000 persons and 67 per 100,000 persons, respectively (Appendix
 207 table 1).

208 In the overall pediatric population, rate ratios comparing jurisdictions in the lowest pediatric
 209 vaccination coverage quartile (8%–12% for cases and ED visits, 8%–13% for hospital admissions)
 210 (Table 2) to the highest pediatric vaccination coverage quartile (22%–28% for cases, 22%–29%
 211 for ED visits and hospital admissions) during the period of Delta predominance were 2.00 (95%
 212 CI: 1.50–2.67) for cases, 2.96 (95% CI: 2.13–4.11) for emergency department visits, and 2.76

213 (95% CI: 2.04–3.74) for hospital admissions (Table 1, Figure 2). In contrast, during the Omicron
214 period of predominance, low coverage jurisdictions (19%–27%) relative to high coverage
215 jurisdictions (46%–56%) were associated with lower case incidence: (0.64 (95% CI: 0.45–0.91)).
216 Vaccination coverage was not associated with emergency department visits (1.11 (95% CI: 0.85–
217 1.44)) and hospital admissions (1.01 (95% CI: 0.80–1.28)) during the Omicron period of
218 predominance (Table 1).

219 During the 3-week peak period of the Delta variant, rate ratios comparing jurisdictions in the
220 lowest pediatric vaccination coverage quartile to the highest pediatric vaccination coverage
221 quartile were more robust 3.19 (95% CI: 2.11–4.82) for cases, 3.41 (95% CI: 2.41–4.82) for
222 emergency department visits, and 3.73 (95% CI: 2.70–5.14) for hospital admissions (Table 1,
223 Figure 2). During the 3-week peak period of the Omicron variant, this association was more robust
224 for emergency department visits: 1.28 (95% CI: 0.95–1.74).

225 When assessing the outcomes by age for cases and emergency department visits during the Delta
226 period, differences were observed in the magnitude of the associations (Table 1). Children aged
227 12–15 and 16–17 years in the jurisdictions with the lowest vaccination coverage had a similar 2.30
228 (95% CI: 1.71–3.08) to 2.18 (95% CI: 1.61–2.95)-fold difference in the incidence of cases
229 compared with jurisdictions with highest vaccination coverage, whereas this difference was 1.78-
230 fold for children aged 5–11 years (95% CI: 1.34–2.37). Similarly, for emergency department visits,
231 the strongest association with vaccination coverage levels by quartile were observed in children
232 aged 12–15 (RR: 3.30, 95% CI: 2.38–4.58) and 16–17 (RR: 3.08, 95% CI: 2.28–4.17) years, versus
233 5–11 (RR: 2.68, 95% CI: 1.89–3.82) years. Findings were even more robust during the 3-week
234 peak period of the Delta variant than during the full Delta period when stratifying by age group.
235 For the Omicron period, low vaccination quartile at the state level coverage was statistically

236 associated with lower case incidence for all age groups. Lowest vaccine coverage was
237 significantly associated with greater emergency department visits among those aged 12–15 (RR:
238 1.39, 95% CI: 1.02–1.90) and 16–17 (RR: 1.34, 95% CI: 1.00–1.78) years during the 3-week peak
239 period (Table 1).

240 **Table 1:** Rate ratios among children aged 5–17 years by outcome comparing COVID-19 pediatric vaccination coverage quartiles of states to states in the highest
 241 vaccination coverage quartile during Delta and Omicron predominant periods – by age group and overall

Outcome	State Vaccination Coverage Quartile	Rate Ratio (95% CIs)															
		5–11				12–15				16–17				All ^a			
		Delta		Omicron		Delta		Omicron		Delta		Omicron		Delta		Omicron	
		Full ^b	Peak ^c	Full ^d	Peak ^e	Full	Peak	Full	Peak	Full	Peak	Full	Peak	Full	Peak	Full	Peak
Cases ^f	Highest	Reference															
	Second Highest	1.25 (0.99, 1.58)	1.14 (0.82, 1.58)	0.65 (0.49, 0.85)	0.63 (0.43, 0.92)	1.24 (0.98, 1.56)	1.16 (0.81, 1.66)	0.72 (0.55, 0.94)	0.73 (0.49, 1.09)	1.26 (1.01, 1.58)	1.24 (0.91, 1.69)	0.78 (0.59, 1.03)	0.79 (0.52, 1.23)	1.25 (0.99, 1.57)	1.16 (0.83, 1.62)	0.69 (0.53, 0.91)	0.69 (0.46, 1.02)
	Second Lowest	1.54 (1.24, 1.91)	2.05 (1.44, 2.91)	0.71 (0.48, 1.03)	0.77 (0.49, 1.23)	1.85 (1.49, 2.30)	2.60 (1.82, 3.72)	0.80 (0.57, 1.13)	0.92 (0.59, 1.45)	1.84 (1.49, 2.28)	2.48 (1.80, 3.43)	0.84 (0.61, 1.16)	0.96 (0.61, 1.51)	1.68 (1.36, 2.08)	2.29 (1.62, 3.23)	0.76 (0.54, 1.08)	0.85 (0.54, 1.34)
	Lowest	1.78 (1.34, 2.37)	2.78 (1.86, 4.15)	0.61 (0.42, 0.88)	0.60 (0.37, 0.96)	2.30 (1.71, 3.08)	3.78 (2.46, 5.83)	0.66 (0.47, 0.94)	0.67 (0.42, 1.07)	2.18 (1.61, 2.95)	3.40 (2.22, 5.21)	0.69 (0.48, 0.97)	0.70 (0.43, 1.12)	2.00 (1.50, 2.67)	3.19 (2.11, 4.82)	0.64 (0.45, 0.91)	0.64 (0.40, 1.02)
Emergency	Highest	Reference															

Department t Visits ^g	Second	1.83	2.09	0.94	1.07	2.06	2.60	1.05	1.20	1.87	2.02	1.04	1.18	1.90	2.21	0.99	1.14
	Highest	(1.13, 2.97)	(1.19, 3.65)	(0.75, 1.17)	(0.81, 1.42)	(1.22, 3.50)	(1.43, 4.72)	(0.85, 1.29)	(0.91, 1.60)	(1.10, 3.19)	(1.06, 3.84)	(0.84, 1.29)	(0.88, 1.58)	(1.15, 3.15)	(1.23, 3.97)	(0.80, 1.22)	(0.86, 1.50)
	Second Lowest	2.16	2.25	1.02	1.14	2.59	2.84	1.16	1.32	2.41	2.41	1.13	1.26	2.34	2.45	1.08	1.22
		(1.41, 3.30)	(1.45, 3.52)	(0.78, 1.33)	(0.86, 1.53)	(1.77, 3.80)	(1.88, 4.29)	(0.91, 1.48)	(1.00, 1.74)	(1.68, 3.45)	(1.60, 3.62)	(0.89, 1.43)	(0.95, 1.68)	(1.59, 3.44)	(1.62, 3.70)	(0.84, 1.39)	(0.92, 1.62)
	Lowest	2.68	2.95	1.03	1.19	3.30	4.07	1.19	1.39	3.08	3.46	1.18	1.34	2.96	3.41	1.11	1.28
		(1.89, 3.82)	(2.09, 4.18)	(0.77, 1.37)	(0.87, 1.64)	(2.38, 4.58)	(2.89, 5.74)	(0.92, 1.54)	(1.02, 1.90)	(2.28, 4.17)	(2.38, 5.02)	(0.93, 1.50)	(1.00, 1.78)	(2.13, 4.11)	(2.41, 4.82)	(0.85, 1.44)	(0.95, 1.74)
Hospital Admission s ^h	Highest	Reference															
	Second Highest													1.97	2.25	1.30	1.22
														(1.27, 3.06)	(1.23, 4.10)	(1.00, 1.69)	(0.91, 1.64)
	Second Lowest													2.67	3.04	1.36	1.19
														(1.61, 4.44)	(1.60, 5.77)	(0.98, 1.89)	(0.87, 1.63)
	Lowest													2.76	3.73	1.01	1.04
														(2.04, 3.74)	(2.70, 5.14)	(0.80, 1.28)	(0.81, 1.34)

242 ^a Hospital admission data are only available in aggregate for children aged 0–17 years during these periods. For cases and ED visits, data are shown for pediatric
243 patients aged 5–17 years. ^b Full period of Delta predominance defined as June 20, 2021 through October 31, 2021
244 ^c Peak period of Delta predominance defined as August 22, 2021 through September 11, 2021
245 ^d Full period of Omicron predominance defined as December 19, 2021 through April 30, 2022
246 ^e Peak period of Omicron predominance defined as January 2, 2022 through January 22, 2022
247 ^f Jurisdictions excluded from case data source include Alaska, Connecticut, District of Columbia, Florida, Kentucky, Hawaii, Iowa, Maryland, Missouri,
248 Mississippi, Nebraska, New Hampshire, Oklahoma, Rhode Island, South Dakota, Texas, Wisconsin, and West Virginia
249 ^g Jurisdictions excluded from emergency department data source include California, Hawaii, Iowa, Minnesota, Oklahoma, Missouri, and Maryland
250 ^h No jurisdictions were excluded from hospital admission data source
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281

282 **Table 2:** Complete vaccination coverage ranges by state coverage quartile for midpoints^a of Delta and Omicron predominant time periods

Outcome	Coverage Quartile Group	Delta	Omicron
Cases ^b	Highest	22-28%	46-56%
	Second Highest	18-22%	34-45%
	Second Lowest	14-17%	27-34%
	Lowest	8-12%	19-27%
Emergency Department Visits ^c	Highest	22-29%	45-56%
	Second Highest	17-21%	34-43%
	Second Lowest	13-17%	27-34%
	Lowest	8-12%	19-27%
Hospital Admissions ^d	Highest	22-29%	46-56%
	Second Highest	17-22%	35-46%
	Second Lowest	14-17%	27-34%
	Lowest	8-13%	19-27%

283 ^a Midpoints of Delta and Omicron periods of predominance defined as August 22, 2021 and February 20, 2022

284 ^b Jurisdictions excluded from case data source include Alaska, Connecticut, District of Columbia, Florida, Kentucky, Hawaii, Iowa, Maryland, Missouri,
 285 Mississippi, Nebraska, New Hampshire, Oklahoma, Rhode Island, South Dakota, Texas, Wisconsin, and West Virginia

286 ^c Jurisdictions excluded from emergency department data source include California, Hawaii, Iowa, Minnesota, Oklahoma, Missouri, and Maryland

287 ^d No jurisdictions were excluded from hospital admission data source

288

289


290

291

292


293 **Figure 2:** Weekly rate ratios among children aged 5–17 comparing lowest COVID-19
 294 vaccination coverage quartile states to highest coverage quartile states by outcome: December
 295 13, 2020–April 30, 2022

Weekly Case Incidence and Rate Ratios for Children Aged 5-17 Years: Low Coverage States vs. High Coverage States
 December 13, 2020 to April 30, 2022




296

Weekly Emergency Department Visits and Rate Ratios for Children Aged 5-17 Years: Low Coverage States vs. High Coverage States
 December 13, 2020 to April 30, 2022



297

Weekly Hospital Admissions and Rate Ratios for Children Aged 0-17 Years: Low Coverage States vs. High Coverage States
 December 13, 2020 to April 30, 2022



298

299 *Vaccine coverage estimates for children aged 5-17 years during the first and last week of the Delta and Omicron*
 300 *periods of predominance in the US: (Delta: 9.21% as of the week of June 20th, 2021, 22.57% the week of October*
 301 *31, 2021); (Omicron: 29.19% the week of December 19, 2021, 40.03% the week of April 24, 2022)*

302 *Full vaccination coverage ranges for bottom and top quartile states as of the week of April 24, 2022: Bottom*
303 *quartile: 20.14%–28.46%, Top quartile: 47.24%–59.42%*

304

305 **Discussion**

306 In this comprehensive ecological analysis, we found that in the United States, during the period of
307 COVID-19 Delta predominance, the rate of cases, emergency department visits, and hospital
308 admissions were 2.00, 2.96, and 2.76 times as high, respectively, in jurisdictions with the lowest
309 vaccination coverage compared with jurisdictions with the highest vaccination coverage. These
310 associations were even more robust during the 3-week peak period of the Delta variant wave. This
311 overall association was not seen during the 3-week peak period of the Omicron wave; however,
312 children (aged 12–15 and 16–17 years) in jurisdictions with the lowest vaccination coverage had
313 higher emergency department visits during this period.

314 This study mirrors the findings of recent formal vaccine effectiveness (VE) evaluations, which
315 have found lower effectiveness during Omicron predominance compared to Delta, especially for
316 the primary series alone^[11-13,22-23]. During both periods, higher VE has been observed for more
317 severe disease (e.g., hospital admissions; death), similar to our finding of a bigger impact of higher
318 coverage on admissions and emergency department visits compared with case counts.

319 Consistent with our findings, the Coronavirus Disease 19 – Associated Hospitalization
320 Surveillance Network (COVID-NET) found large increases in the rates of COVID-19-associated
321 hospital admissions during Delta period; the monthly rate in December 2021 among unvaccinated
322 children aged 12–17 years was six times that of vaccinated children^[20, 22-24].

323 Several possible explanations may explain the discordant findings regarding higher vaccine
324 coverage and higher case incidence in this study and in an analysis of 68 countries and 2947

325 counties in the United States^[25]. These explanations include unmeasured confounders including
326 differences in population, vaccine products and schedules, and variant circulation during the study
327 periods; very low vaccine coverage among children aged 5–11 years compared with adults;^[26,27]
328 and waning vaccine immunity (5 months after completing a vaccine series)^[28,29]. In addition to
329 vaccination coverage, other factors may have affected COVID-19 incidence. Differences other
330 than vaccine coverage (e.g., testing patterns, local and state COVID-related policies impacting
331 school closures and mask mandates, behavior, socio-economic status, urban/rural divide) could
332 have impacted rates of disease and were not accounted for in this analysis.

333 This analysis has several limitations. First, causation between pediatric vaccination coverage and
334 outcomes cannot be inferred since this was an ecological study; pediatric vaccine effectiveness has
335 been shown by other studies^[23]. Second, there are limitations within data sources including lack of
336 granular age data prior to February 2022 for hospital admissions data and data quality limitations
337 for both case and emergency department data, leading to exclusion of some localities and
338 jurisdictions. Nonetheless, pediatric populations in the included and excluded states were similar
339 in regard to the distribution of their age groups, sex, and distribution by social vulnerability
340 index^[19] (a measure of stressors with negative effects on communities) levels (Supplementary table
341 2). Third, differences in SARS-CoV-2 testing between jurisdictions with high versus low coverage
342 could not be determined and may have biased our findings. For instance, if low coverage
343 jurisdictions tested less, this would lower estimates of COVID-19 case incidence in these
344 jurisdictions, and thus, potentially bias results showing less impact of the vaccine on cases.
345 However, this would less likely affect severe outcomes (e.g., emergency department visits, and
346 hospital admissions), where a greater impact of vaccination coverage on emergency department
347 visits and hospital admissions was observed, when compared with cases. Finally, boosters were

348 not approved for the youngest pediatric age group during the Delta and Omicron periods; therefore,
349 the analysis was not able not assess the impact of additional doses after completion of the primary
350 series.

351 In conclusion, during the COVID-19 Delta and Omicron waves, COVID-19 vaccination was
352 associated with reduced COVID-19 burden on the healthcare system. Higher vaccination rates
353 were associated with lower rates of cases, hospital admissions and emergency department visits
354 among pediatric age groups approved to receive COVID-19 vaccine during the Delta period. A
355 reduction in emergency department visits, but not cases or hospital admissions, was observed
356 during the Omicron period. COVID-19 vaccines are safe and effective in preventing severe
357 outcomes among the pediatric population^[12]. Pediatric COVID-19 vaccinations are recommended
358 to prevent COVID-related outcomes among children^[1-3].

359

360

361

362

363

364

365

366

367

368

369

370

371 References

- 372 1. Oliver SE, Gargano JW, Marin M, et al. The Advisory Committee on Immunization
373 Practices' interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine —
374 United States, December 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69:1922-1924.
375 doi:10.15585/mmwr.mm6950e2.
- 376 2. Wallace M, Woodworth KR, Gargano JW, et al. The Advisory Committee on
377 Immunization Practices' interim recommendation for use of Pfizer-BioNTech COVID-19
378 vaccine in adolescents aged 12–15 years — United States, May 2021. *MMWR Morb*
379 *Mortal Wkly Rep.* 2021;70:749–752. doi:10.15585/mmwr.mm7020e1.
- 380 3. Woodworth KR, Moulia D, Collins JP, et al. The Advisory Committee on Immunization
381 Practices' interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine in
382 children aged 5–11 years — United States, November 2021. *MMWR Morb Mortal Wkly*
383 *Rep.* 2021;70:1579–1583. doi:10.15585/mmwr.mm7045e1.
- 384 4. Trends in demographic characteristics of people receiving COVID-19 vaccinations in the
385 United States. US Centers for Disease Control and Prevention. Accessed May 24, 2022.
386 <https://covid.cdc.gov/covid-data-tracker/#vaccination-demographic-trends>.
- 387 5. Siebach MK, Piedimonte G, Ley SH. COVID-19 in childhood: Transmission, clinical
388 presentation, complications and risk factors. *Pediatr Pulmonol.* 2021 Jun;56(6):1342-
389 1356. doi: 10.1002/ppul.25344.
- 390 6. COVID Data Tracker. Centers for Disease Control and Prevention. Accessed May 20,
391 2022. <https://covid.cdc.gov/covid-data-tracker>.
- 392 7. Yasuhara J, Watanabe K, Takagi H, et al. COVID-19 and multisystem inflammatory
393 syndrome in children: A systematic review and meta-analysis. *Pediatr Pulmonol.*
394 2021;56(5):837-848. doi: 10.1002/ppul.25245.
- 395 8. Rajmil L, Hjern A, Boran P, et al. Impact of lockdown and school closure on children's
396 health and well-being during the first wave of COVID-19: A narrative review. *BMJ*
397 *Paediatr Open.* 2021;5(1):e001043. doi: 10.1136/bmjpo-2021-001043.
- 398 9. McNamara LA, Wiegand RE, Burke RM, et al. Estimating the early impact of the US
399 covid-19 vaccination programme on COVID-19 cases, emergency department visits,
400 hospital admissions, and deaths among adults aged 65 years and older: An ecological
401 analysis of national surveillance data. *The Lancet.* 2022;399(10320):152-160.
402 doi:10.1016/s0140-6736(21)02226-1.
- 403 10. Suthar, AB, Wang, J, Seffren, V, et al. Public health impact of covid-19 vaccines in the
404 US: Observational study. *BMJ.* 2022;377. doi:10.1136/bmj-2021-069317.
- 405 11. Fowlkes AL, Yoon SK, Lutrick K, et al. Effectiveness of 2-dose BNT162b2 (Pfizer
406 BioNTech) mRNA vaccine in preventing SARS-CoV-2 infection among children aged 5–
407 11 years and adolescents aged 12–15 Years — PROTECT Cohort, July 2021–February
408 2022. *MMWR Morb Mortal Wkly Rep.* 2022;71:422–428.
409 doi:10.15585/mmwr.mm7111e1.
- 410 12. Klein NP, Stockwell MS, Demarco M, et al. Effectiveness of COVID-19 Pfizer-
411 BioNTech BNT162b2 mRNA vaccination in preventing COVID-19-associated

- 412 emergency department and urgent care encounters and hospitalizations among
413 nonimmunocompromised children and adolescents aged 5–17 years — VISION network,
414 10 states, April 2021–January 2022. *MMWR Morb Mortal Wkly Rep.* 2022;71:352–358.
415 doi:10.15585/mmwr.mm7109e3.
- 416 13. Fleming-Dutra KE, Britton A, Shang N, et al. Association of Prior BNT162b2 COVID-
417 19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents
418 During Omicron Predominance. *JAMA.* 2022;327(22):2210-2219.
419 doi:10.1001/jama.2022.7493
- 420 14. Information for health departments on reporting cases of COVID-19. US Centers for
421 Disease Control and Prevention. Accessed May 4, 2022.
422 <https://www.cdc.gov/coronavirus/2019-ncov/php/reporting-pui.html>.
- 423 15. National Notifiable Diseases Surveillance System (NNDSS). US Centers for Disease
424 Control and Prevention. Accessed May 4, 2022. <https://www.cdc.gov/nndss/>.
- 425 16. National Syndromic Surveillance Program (NSSP). US Centers for Disease Control and
426 Prevention. Accessed May 4, 2022. <https://www.cdc.gov/nssp/index.html>.
- 427 17. Unified hospital dataset 2021. US Centers for Disease Control and Prevention. Accessed
428 May 4, 2022. <https://covid.cdc.gov/coviddata-tracker/#abouthospitaldata>.
- 429 18. About COVID-19 vaccine delivered and administration data 2021. US Centers for
430 Disease Control and Prevention. Accessed May 4, 2022. <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/distributing/about-vaccinedata.html>.
- 431 19. Hughes MM, Wang A, Grossman MK, et al. County-level COVID-19 vaccination
432 coverage and social vulnerability—United States, December 14, 2020–March 1, 2021.
433 *MMWR Morb Mortal Wkly Rep.* 2021; 70(12): 431–36. doi: 10.15585/mmwr.mm7012e1.
- 434 20. Marks KJ, Whitaker M, Anglin O, et al. Hospitalizations of children and adolescents with
435 laboratory-confirmed COVID-19 — COVID-NET, 14 states, July 2021–January 2022.
436 *MMWR Morb Mortal Wkly Rep.* 2022;71:271–278. doi:10.15585/mmwr.mm7107e4.
- 437 21. 2019 Population Estimates by Age, Sex, Race and Hispanic Origin (census.gov).
438 www.census.gov/newsroom/press-kits/2020/population-estimates-detailed.html.
439 Accessed July 1, 2022.
- 440 22. Tenforde MW, Self WH, Gaglani M, et al. Effectiveness of mRNA vaccination in
441 preventing COVID-19–associated invasive mechanical ventilation and death — United
442 States, March 2021–January 2022. *MMWR Morb Mortal Wkly Rep.* 2022;71:459–465.
443 doi:10.15585/mmwr.mm7112e1.
- 444 23. Accorsi EK, Britton A, Fleming-Dutra KE, et al. Association between 3 doses of mRNA
445 COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 omicron and
446 delta variants. *JAMA.* 2022;327(7):639–651. doi:10.1001/jama.2022.0470.
- 447 24. Shi DS, Whitaker M, Marks KJ, et al. Hospitalizations of Children Aged 5–11 Years with
448 Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 2020–February
449 2022. *MMWR Morb Mortal Wkly Rep.* 2022;71(16):574-581.
450 doi:10.15585/mmwr.mm7116e1.
- 451 25. Subramanian SV, Kumar A. Increases in COVID-19 are unrelated to levels of
452 vaccination across 68 countries and 2947 counties in the United States. *Eur J Epidemiol.*
453 2021;36(12):1237-1240. doi:10.1007/s10654-021-00808-7
454

- 455 26. Murthy NC, Zell E, Fast HE, et al. Disparities in First Dose COVID-19 Vaccination
456 Coverage among Children 5-11 Years of Age, United States. *Emerg Infect Dis.*
457 2022;28(5):986-989. doi:10.3201/eid2805.220166
- 458 27. Diesel J, Sterrett N, Dasgupta S, et al. COVID-19 Vaccination Coverage Among Adults -
459 United States, December 14, 2020-May 22, 2021. *MMWR Morb Mortal Wkly Rep.*
460 2021;70(25):922-927. Published 2021 Jun 25. doi:10.15585/mmwr.mm7025e1
- 461 28. Menni C, May A, Polidori L, et al. COVID-19 vaccine waning and effectiveness and
462 side-effects of boosters: a prospective community study from the ZOE COVID Study
463 [published online ahead of print, 2022 Apr 8]. *Lancet Infect Dis.* 2022;S1473-
464 3099(22)00146-3. doi:10.1016/S1473-3099(22)00146-3
- 465 29. Andrews N, Stowe J, Kirsebom F, et al. Covid-19 Vaccine Effectiveness against the
466 Omicron (B.1.1.529) Variant. *N Engl J Med.* 2022;386(16):1532-1546.
467 doi:10.1056/NEJMoa211

medRxiv preprint doi: <https://doi.org/10.1101/2022.10.07.22280822>; this version posted October 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.